Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 12

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 12
---
12 to 24 months), the timing of initiation and completion of studies or trials and related preparatory work, the period during 
 which the results of the trials will become available and our research and development programs;                                                                                                                                                       |

| ∎ |     | the anticipated timing of releasing data for current or future clinical trials; |

| ∎ |     | the anticipated timing of commencement, enrollment, and completion of any current or future clinical trials for the ADC 
 Therapies or any other product candidates we may develop;                                                               |

| ∎ |     | our belief that, with the three ADC Therapies, we have the ability to pursue multiple cancer indications with high                                           
 potential in large addressable patient populations, including and beyond those indications currently expected to be targeted in the upcoming Phase 1 trials; |

| ∎ |     | our belief that the ADC Therapies will be able to target cancers expressing specified tumor markers precisely and deliver 
 the potent, cytotoxic TOPO1 inhibitor at the site of cancer;                                                              |

| ∎ |     | our view that we are positioned to unlock the high potential of our ADC portfolio due to our track record of strong                                             
 execution of novel drug formulation, research, clinical development, and commercialization in precision oncology, combined with our deep understanding of ADCs; |

| ∎ |     | our belief that our team is well positioned to execute on our strategy to develop and, if approved, commercialize the ADC 
 Therapies and future pipeline assets to ultimately bring broad benefit to cancer patients worldwide;                      |

| ∎ |     | our manufacturing capabilities and strategy; |

| ∎ |     | the expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of the ADC Therapies 
 and any other product candidates that we may develop;                                                                    |

| ∎ |     | the implementation of our business model and our strategic plans for our business; |

| ∎ |     | our ability to contract with and rely on third parties to assist in conducting our clinical trials and manufacturing the 
 ADC Therapies and any other product candidates we may develop in the future;                                             |

S-10

| ∎ |     | the size and growth potential of the markets for the ADC Therapies and any other product candidates we may develop, if 
 approved, and our ability to serve those markets, either alone or in partnership with others;                          |

| ∎ |     | our ability to obtain funding for our operations, including funding necessary to complete development,